Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 14/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 14/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.43 |
| ▸ | ITGAV | P06756 | 9/20 | 0.43 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568643 | 0.86 | ITGB1 (0.51) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL5565780 | 0.86 | ITGB1 (0.51) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL5568305 | 0.86 | ITGB1 (0.51) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL14453497 | 0.86 | ITGB1 (0.51) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL5565775 | 0.86 | ITGB1 (0.51) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL5561213 | 0.81 | ABCB1 (0.49) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL8288105 | 0.81 | PREP (0.42) | POLBPARP1 | |
| SCHEMBL14453495 | 0.80 | ITGB1 (0.56) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL15152613 | 0.79 | ITGB1 (0.51) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL5566425 | 0.79 | ITGB1 (0.51) | ITGB1ITGA5ITGB3ITGAVITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727811-B1 | NEW COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND USE OF THEREOF | SHIRE ORPHAN THERAPIES GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-8501787-B2 | Compounds for the inhibition of angiogenesis and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-8501787-B2 | Compounds for the inhibition of angiogenesis and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-8501787-B2 | Compounds for the inhibition of angiogenesis and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20070155712-A1 | Compounds for the inhibition of angiogenesis and use thereof | JERINI AG (DE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155712-A1 | Compounds for the inhibition of angiogenesis and use thereof | JERINI AG (DE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155712-A1 | Compounds for the inhibition of angiogenesis and use thereof | JERINI AG (DE) | 2007-07-05 | — | — | US | disclosed |
| WO-2005090329-A9 | NEW COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND USE OF THEREOF | JERINI AG (DE) | 2007-02-01 | — | — | WO | disclosed |
| EP-1727811-A1 | NEW COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND USE OF THEREOF | Jerini AG (DE) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005090329-A1 | NEW COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND USE OF THEREOF | JERINI AG (DE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155712-A1 | Compounds for the inhibition of angiogenesis and use thereof | ITGAV, VCAM1, ITGA5 | ITGB1 9/4885ITGA5 3/4885ITGB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.